At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Enzalutamide +1 moredrug
Likely dose
Enzalutamide 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Enzalutamide and Talazoparib for Metastatic Prostate Cancer. Completed, enrolled 54 participants across 8 sites.
Detailed Summary
This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate cancer (mHNPC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesSpain
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartSep 2020
Primary CompletionMay 2025
TodayJul 2026
First PostedApr 3, 2020
Enrollment StartSep 2, 2020
Primary CompletionMay 6, 2025
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 6.2 years ago
Interventions
Enzalutamidedrug
Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
Talazoparibdrug
Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)